8-K: STRATA Skin Sciences Q3 2025: Revenue Declines Amid Strategic Gains

STRATA Skin Sciences reported a 21% revenue decline in Q3 2025 to $6.9 million, alongside positive EBITDA and significant progress on CPT code expansion for its XTRAC laser.

Summary

• Revenue for the third quarter of 2025 was $6.9 million, a 21% decrease compared to $8.797 million in the third quarter of 2024.
• Global recurring revenue increased 3% year-over-year to $5.5 million, while equipment revenue decreased 60% to $1.4 million.
• Gross profit for the quarter was $4.2 million, or 60% of revenue, down from $5.3 million in the prior-year period.
• Net loss for Q3 2025 improved to $1.6 million (EPS of -$0.36) from a net loss of $2.1 million (EPS of -$0.51) in Q3 2024.
• EBITDA was slightly positive in Q3 2025, compared to negative $0.2 million in the comparable prior-year period.
• Cash and cash equivalents at September 30, 2025, stood at $7.1 million, following a $2.4 million registered direct offering.
• Average gross billings per device increased 8.5% to $5,981, marking the highest level since the fourth quarter of 2022.
• The U.S. install base of XTRAC devices declined by 6 during the third quarter of 2025, to 838.
• The U.S. install base of TheraClearX devices is 161.
• Significant progress was made toward the historic expansion of CPT codes for reimbursement for inflammatory and auto-immune skin diseases, potentially tripling the covered patient population in the US, with recent recognition by the CMS 2026 final PFS rule.
• COFEPRIS (Mexican regulatory agency) clearance of TheraClearX in Mexico and first commercial placements were achieved.
• Positive developments occurred in the ongoing lawsuit against LaserOptek, with the addition of LaserOptek Korea and C. Dalton, LLC as defendants, improving opportunities for collecting damages.
• Dozens of partner clinics previously lost to LaserOptek were recaptured.

Sentiment

Score: 5

Explanation: The company reported a significant revenue decline and decreased equipment sales, indicating current operational challenges. However, recurring revenue showed growth, net loss improved, and strategic initiatives like CPT code expansion, positive litigation outcomes, and international market entry for TheraClearX offer strong future growth potential, balancing the current financial headwinds.

Positives

• Net loss improved to $1.6 million (EPS -$0.36) in Q3 2025 from $2.1 million (EPS -$0.51) in Q3 2024.
• EBITDA was slightly positive in Q3 2025, a significant improvement from negative $0.2 million in the comparable prior-year period.
• Global recurring revenue increased 3% year-over-year to $5.5 million.
• Average gross billings per device increased 8.5% to $5,981, representing the highest level since Q4 2022.
• Significant progress was made toward CPT code expansion for inflammatory and auto-immune skin diseases, effectively tripling the covered patient population in the US, with recent recognition by the CMS 2026 final PFS rule.
• TheraClearX received COFEPRIS clearance in Mexico, leading to first commercial placements.
• Multiple new peer-reviewed publications further validated XTRAC's clinical outcomes, including combination therapies and breakthrough therapy for localized atopic dermatitis.
• Positive developments in the ongoing lawsuit against LaserOptek, including the addition of new defendants, are expected to improve damage collection.
• Dozens of partner clinics previously lost to LaserOptek were successfully recaptured.

Negatives

• Total revenue declined by 21% to $6.9 million in Q3 2025 compared to $8.797 million in Q3 2024.
• Total revenue declined by approximately $1.9 million due to softness in international markets, primarily driven by instability in international trade policy.
• Equipment revenue decreased 60% year-over-year to $1.4 million.
• Gross profit decreased to $4.2 million from $5.3 million in Q3 2024.
• The U.S. install base of XTRAC devices declined by 6 during the third quarter of 2025, to 838.

Risks

• Softness in international markets driven primarily by instability in international trade policy.
• General financial, economic, business, competitive, market, and regulatory risks.
• Adverse market conditions, labor supply shortages, or supply chain interruptions resulting from fiscal, political factors, international conflicts, responses, or conditions affecting the Company, the medical device industry, and customers and patients.
• Uncertainties regarding the Company's ability to launch and sell products, develop social media and direct-to-consumer marketing campaigns, and build a leading franchise in dermatology and aesthetics.

Future Outlook

The company anticipates growth in the coming quarters driven by the newly approved reimbursement codes for XTRAC, which are expected to expand interest from patients and practitioners. Positive outcomes in ongoing litigation are also expected to translate into increased revenue. Management plans to continue carefully managing costs, strategically expanding the patient pool through direct-to-consumer efforts, and strengthening practice partners through consulting services.

Management Comments

• We continue to see solid recurring revenue expansion in partner clinics with meaningful growth in same store sales.
• We are further excited for the potential in growth in the coming quarters based on anticipation of the newly approved reimbursement codes in new indications for our XTRAC Excimer laser treatment.
• Recent acknowledgement of these codes by the Centers for Medicare and Medicaid Services are helping to expand interest from patients and practitioners alike in the expanded potential for new treatments and additional revenue streams, respectively.
• XTRAC has become the established gold standard in narrow band UVB treatment for skin disorders, and we continue to refine our business, as well as provide important resources for our clinician partners, that we believe will continue to yield positive results and growth.
• In the meantime, positive outcomes in our ongoing litigation have brought new customers to the fold, which we anticipate will ultimately translate to increased revenue over the coming quarters.
• In the meantime, as always, we continue to carefully manage costs and strategically expand our patient pool through our DTC efforts, while strengthening our practice partners through our consulting services.

Industry Context

The medical technology industry for dermatologic conditions is experiencing advancements in treatment options, particularly for inflammatory and auto-immune skin diseases. The expansion of CPT codes by CMS for excimer laser treatments signifies a positive regulatory trend that could significantly increase market access and patient volume for companies in this niche. The validation of combination therapies and breakthrough treatments through peer-reviewed publications indicates a focus on enhancing efficacy and expanding indications within the dermatology device sector.

Comparison to Industry Standards

• XTRAC is positioned as the 'established gold standard' in narrow band UVB treatment for skin disorders.
• The company holds patents for combination treatments involving XTRAC with JAK inhibitors for vitiligo and topical drugs for psoriasis, positioning it as the 'only clinically proven and intellectual property protected solution' in these specific areas.
• No specific comparable companies, projects, or numerical benchmarks were provided in the filing for direct industry comparison.

Legal Proceedings

• Ongoing lawsuit against LaserOptek with positive developments, including the addition of LaserOptek Korea and C. Dalton, LLC as defendants, which is expected to improve the opportunity for collecting damages.

Stakeholder Impact

• Shareholders: Mixed impact due to current revenue decline but improved net loss and strong future growth potential from strategic initiatives like CPT code expansion and positive litigation outcomes.
• Customers (Clinics): Benefit from recaptured clinics, consulting services, and co-op advertising support. Potential for increased patient volume and revenue streams due to CPT code expansion.
• Patients: Potential for expanded access to XTRAC treatments for inflammatory and auto-immune skin diseases due to CPT code expansion.
• Employees: Continued focus on managing costs and strategic expansion may impact resource allocation and operational priorities.

Next Steps

• Continue progress toward the historic expansion of CPT codes for reimbursement for inflammatory and auto-immune skin diseases.
• Further refine the business and provide important resources for clinician partners.
• Carefully manage costs and strategically expand the patient pool through DTC efforts.
• Strengthen practice partners through consulting services.
• Host an earnings conference call on November 13, 2025, to review financial results and provide a corporate update.

Key Dates

Recommendation

The significant revenue decline and drop in equipment sales are concerning, indicating current market challenges, particularly internationally. However, the growth in recurring revenue, improved net loss, and the substantial future potential from the CPT code expansion and positive litigation outcomes provide a strong counterbalance. The company is in a transitional phase, with strategic initiatives poised to drive future growth, but current financial performance is weak. A 'hold' recommendation allows investors to monitor the execution of these strategic initiatives and the realization of their benefits without exiting a potentially undervalued asset.

Keywords

STRATA Skin Sciences, SSKN, Q3 2025, financial results, dermatology, medical technology, XTRAC laser, TheraClearX, CPT codes, CMS, vitiligo, psoriasis, acne, autoimmune skin diseases, excimer laser, earnings report